Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study for the Evaluation of the Feasibility of Lazertinib 160mg Per Day in Patients With EGFR T790M Mutant Non-small Cell Lung Cancer

NCT05701384 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT05701384
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05701384 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study for the Evaluation of the Feasibility of Lazertinib 160mg Per Day in Patients With EGFR T790M Mutant Non-small Cell Lung Cancer
Lead sponsor
Samsung Medical Center
Phase
Phase 2
Overall status
Unknown status
Start date
February 1, 2023
Completion date
January 31, 2025
Enrollment
117 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

egfr t790m, lung cancer stage iv